WebThe aim of the study is to compare the efficacy, safety, and cost-effectiveness of clarithromycin-based bismuth-containing quadruple therapy (C-BQT) and furazolidone-based bismuth-containing quadruple therapy (F-BQT) in naïve H. pylori positive patients. Methods: This was an open-label, randomized controlled, crossover trial. WebNov 26, 2024 · Brief Summary: The purpose of this study is to assess and compare the effectiveness of furazolidone-tetracycline-containing and metronidazole-tetracycline-containing quadruple regimens for the rescue treatment of Helicobacter pylori infection inpatients allergic to penicillin. Detailed Description:
Furazolidone combination therapies for Helicobacter pylori …
WebConclusion: furazolidone-, rifabutin-, and sitafloxacin-based therapies might be considered as alternative regimens to eradicate H. pylori in Indonesia, including regions with high metronidazole and clarithromycin resistance rates. Moreover, sitafloxacin but not garenoxacin should be considered for eradication of levofloxacin-resistant strains. WebAug 28, 2014 · Aim: To evaluate the efficacy of furazolidone-based triple and quadruple therapy in eradicating Helicobacter pylori (H. pylori) in a multi-center randomized … ralph thull goodtime dutchmen
Safety of furazolidone-containing regimen in Helicobacter …
Web幽门螺杆菌(Helicobacter pylori,Hp)是一种微需氧的革兰阴性菌,定植于人类胃黏膜,与慢性胃炎、消化性溃疡、胃癌和胃黏膜相关的淋巴瘤等疾病的关系密切[1]。根除Hp可以促进溃疡愈合,明显减少溃疡复发,降低胃癌发生的风险。 WebBackground: Antibiotic resistance has begun to impair the ability to cure Helicobacter pylori infection. Aim: To evaluate furazolidone as a component of combination therapies for treatment of H. pylori infection in the United States. Methods: Patients with active H. pylori infection received furazolidone combination therapy for 14 days (furazolidone 100 mg … WebBACKGROUND Furazolidone has been used as an alternative for clarithromycin or metronidazole in Helicobacterpylori (H.pylori) eradication regimens. In Iran, 14-day Furazolidone-containing quadruple regimens have shown promising eradication rates, but short-course, low dose therapies are always attractive. overcoming death ffbe